*Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide*

Team name: Inhibitec-Anticuerpos

Date updated: November 25, 2019

|  |  |
| --- | --- |
| S1: Title& Elevator Pitch/Headline | * Inhibitec-Anticuerpos S.L.
* Psoriatic Arthritis (PsA) is a progressive and destructive joint disease that severely reduces the quality of life of patients with psoriasis.
* BAMBI (BMP and Activin Membrane-Bound Inhibitor) blockade is a new therapeutic option for patients with Psoriatic Arthritis
 |
| S2: The problem and who has it | * More than 125 million individuals (2–3% of global population) are affected by psoriasis and 30% of them also develop PsA.
* With the existing therapies 35-40% of patients with PsA do not reach a minimum level of efficacy (ACR 20% joint response level) and the appearance of drug resistances is frequent.
* There is a need to identify new molecular targets and treatments in PsA that improve existing therapies.
 |
| S3: The solution  | * We have identified BAMBI as a key player in PsA.
* We have developed and anti-mouse and human BAMBI mAb, B101.37, that inhibits BAMBI.
* B101.37 demonstrates in vivo preclinical efficacy in PsA equivalent to existing standard of care.
 |
| S4: Product (how it addresses the problem) | * B101.37simultaneously targets protective Treg (enhance) and harmful TH17 cells (reduce).
* Existing therapies target only the IL-23/IL-17A TH17 axis.
* Future development will position B101.37 as a new gold standard in the management of PsA.
 |
| S5: Technology | * Anti-BAMBI mAb acts on activated CD4+ T cells.
* Anti-BAMBI mAb inhibits the differentiation of pathogenic TH17 CD4+ T cells.
* Anti-BAMBI mAb enhances the differentiation and activity of protective regulatory CD4+ T cells (Tregs).
 |
| S6: Competing approaches | * There exist new treatment with biologics for PsA [Secukinumab and Ixekizumab (anti-IL-17A), Ustekinumab (anti-IL-12 and IL-23)] that exhibit better responses than anti-TNF therapies.
* When B101.37 mAb can arrive to the market, some of these treatments will be available as biosimilars.
* Our anti-BAMBI mAb exhibits similar therapeutic responses than anti-IL-17 mAs in preclinical models of PsA.
 |
| S7:Traction | * Two articles; one already published and the second in revision (both in Arthritis Rheumatol.). Three grants from the Spanish Nacional Agency of Science.
* One patent on National Phases (USA and EC).
* Inhibitec-Anticuerpos External Scientific Board: Prof Gabriel Nuñez, University of Michigan; Prof Miguel López-Botet Universidad Pompeu Fabra; Prof Carlo Chizzolini, University of Geneva; Prof Stéphane Schurmans, University of Liege.
 |
| S8:Team | * Scientists: Ramón Merino, Jesús Merino.
* Partners from Pharma and Biotech industries: Eduardo Quemada, Josep M. Piqueras, Joaquín A. Palma
* Partners with experience in Finance: Eduardo Mesquida, Pascal Vieilledent
 |
| S9:Closing | * We have identified a new molecular target in PsA, BAMBI, and develop inhibitory mAbs against it.
* Inhibitec-Anticuerpos plans to position B101.37 as a new, gold standard therapeutic option in the management of PsA
* Inhibitec-Anticuerpos, Instituto de Biomedicina y Biotecnología de Cantabria, C/ Albert Einstein 22, 39011 Santander, Spain.
 |